Fourteen weeks of liraglutide therapy in subjects with type 2 diabetes significantly improves first phase insulin secretion and maximal beta-cell secretory capacity

被引：0
|
作者：
Madsbad, S.
Brock, B.
Perrild, H.
Lervang, H. H.
Kolendorf, K.
Krarup, T.
Schmitz, O.
Le-Thi, T.
Zdravkovic, M.
Vilsboll, T.
机构：
[1] Hvidovre Univ Hosp, DK-2650 Hvidovre, Denmark
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Bispebjerg Univ Hosp, Copenhagen, Denmark
[4] Aarhus Univ Hosp, Aalborg, Denmark
[5] Roskilde Cty Psychiat Hosp Fjorden, Roskilde, Denmark
[6] Gentofte Univ Hosp, Hellerup, Denmark
[7] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0004
引用
收藏
页码：4 / 5
页数：2
相关论文
共 50 条
  • [21] Effect of Short-Term Intensive Insulin Therapy on Beta-Cell Function in Type 2 Diabetes
    Retnakaran, Ravi
    Yakubovich, Natalia
    Qi, Ying
    Opsteen, Christine
    Zinman, Bernard
    DIABETES, 2009, 58 : A131 - A132
  • [22] The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus
    Del Prato, S
    Tiengo, A
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2001, 17 (03) : 164 - 174
  • [23] Effects of exenatide on first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
    Fehse, FC
    Trautmann, ME
    Holst, JJ
    Halseth, AE
    Fineman, M
    Kim, D
    Nauck, MA
    DIABETES, 2004, 53 : A82 - A82
  • [24] Effects of exenatide on first and second phase insulin secretion in response to intravenous glucose in subjects with Type 2 diabetes
    Fehse, F
    Trautmann, ME
    Holst, JJ
    Halseth, AE
    Fineman, M
    Kim, D
    Nauck, MA
    DIABETOLOGIA, 2004, 47 : A279 - A279
  • [25] Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes
    Anholm, Christian
    Kumarathurai, Preman
    Pedersen, Lene R.
    Nielsen, Olav W.
    Kristiansen, Ole P.
    Fenger, Mogens
    Madsbad, Sten
    Sajadieh, Ahmad
    Haugaard, Steen B.
    DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 850 - 857
  • [26] Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes
    Z. Asghar
    D. Yau
    F. Chan
    D. LeRoith
    C. B. Chan
    M. B. Wheeler
    Diabetologia, 2006, 49 (3) : 615 - 615
  • [27] Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes
    Asghar, Z
    Yau, D
    Chan, F
    LeRoith, D
    Chan, CB
    Wheeler, MB
    DIABETOLOGIA, 2006, 49 (01) : 90 - 99
  • [28] Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes
    Z. Asghar
    D. Yau
    F. Chan
    D. LeRoith
    C. B. Chan
    M. B. Wheeler
    Diabetologia, 2006, 49 : 90 - 99
  • [29] The MetAP2 Inhibitor, ZGN-1061, Improves Insulin Sensitivity and Beta-Cell Function in Patients with Type 2 Diabetes
    Fabunmi, Rosalind
    Bergman, Richard N.
    Piccinini, Francesca
    Kim, Terri
    Zhuang, Dongliang
    Taylor, Kristin
    Kim, Dennis D.
    DIABETES, 2019, 68
  • [30] Calpain inhibitors impair insulin secretion after 48-hours: A model for beta-cell dysfunction in type 2 diabetes?
    Zhou, YP
    Sreenan, S
    Bindokas, VP
    Pan, CY
    Currie, KPM
    Lee, JP
    Fox, AP
    Miller, RJ
    Cox, NJ
    Polonsky, KS
    DIABETES, 2000, 49 : A80 - +
12345